Marc Dunoyer: Yes. So let me pull out some comments on the Ultomiris progression. As you mentioned, very strong portion of the quarter plus 47% regarding the launch of in the U.S. I suppose you refer to the U.S., but we have also launched in other territories. In the U.S the progression in myasthenia gravis is quite good both on the front of the conversion from Soliris. So it is developing as we had expected, but we also very pleased with the progress we make in naive patient, naive to see five patients, so we are — it is progressing as we expected. If we compare, let’s say the start of 2022 and where we are now, we have progressed substantially in the number of patients in myasthenia gravis and we only launched Ultomiris in May of 2022.
So, good progression on the conversion and on the naive patients. Regarding the factor D, we have seen the announcement of factor D and we are looking forward to seeing the presentation that will take place imminently now. We are very interested in the results. On our side we also of progress on all complement inhibitors. And we have a successful Phase III on danicopan as an add on in the same patient population which is patient with developed EVH on C5 therapy. And we have seen very well — we have result they’re very good. We have also Phase II study in PNH on the second factor D that we are progressing. And we have also other indication myasthenia gravis as well as general indication. So, we have — we’ve been very happy to be to have the first-in-class on factor D and we are now developing three factor D in — at clinical stage as a novel treatment in the complement cascade.
Pascal Soriot: Thanks, Marc. Susan, camizestrant.
Susan Galbraith: Yes, so do you think the profile of camizestrant is one that supports its use in the early stages? Obviously, as you’ve seen from the adjuvant studies with CDK4/6 inhibitors, the design of the patient population in the adjuvant setting requires careful balancing of the risks. Patients that are high enough risk so that there is an unmet need in minimizing inclusion of patients unlikely to benefit. So again, we’re confident about the profile that we’ve got with camizestrant. We are moving ahead with the development of this program broadly in the indications where you would expect it to have efficacy.
Pascal Soriot: Maybe let me just add on this that, I said earlier, we have 15 NMEs in Phase III. And we are going to develop each of those products to their full potential. So with camizestrant I guess you can see what I mean with that. But that again takes us back to have to continue our investment in R&D. And we’ll keep our R&D spend at the low 20s as a percentage of our revenue because we have so many huge opportunities that we can unlock on camizestrant side. I have to say Susan and her team did a fantastic job taking their time to identify the right approach, the right dosage, and doing the same now with additional Phase III studies in early treatment. So hopefully we can make camizestrant a very big product. Next question is Seamus Fernandez. Seamus, over to you.
Seamus Fernandez: Hello. Thanks very much for the question. So just two quick ones. First, this is really for Mene. Mene, just trying to understand the opportunity that you see in ATTR. And the reason for the significant increase in the size of the study. Just want to better understand if you guys are either playing for an earlier interim, or a potentially differentiated label, or if you see potential challenges, so that you’re just managing for a potentially different effect size, just given the competitive landscape. So that’s the first question. And then the second one, Aradhana, just wanted to better understand gross margin progression, in particular, we’re seeing higher margin product actually roll in quite significantly on the collaboration revenue line.
